The soluble human CD80 (Hu SCD80) ELISA quantifies Hu sCD80 in human serum, plasma, cell culture supernatants or other body fluids. The dosage will recognize only natural and recombinant Hu sCD80. Principle of...
The soluble human CD80 (Hu SCD80) ELISA quantifies Hu sCD80 in human serum, plasma, cell culture supernatants or other body fluids. The dosage will recognize only natural and recombinant Hu sCD80. Principle of the L-ELISA solid phase sandwich human sCD80 (immuno-enzymatic test) is designed to measure the amount of the target bound between a pair of matched antibodies. A target-specific antibody was pre-vested in the wells of the supplied microplate. Samples or controls are then added to these wells and are linked to immobilized antibodies (capture). The sandwich is formed by binding the second antibody (detector) to the target on a different epitope from the capture antibody. An antibody conjugated with the enzyme binds the formed sandwich. After incubation and washing steps to remove the microplate from the non-bonded substances, a substrate solution reacts with the enzyme-antibodies-target complex to produce a measurable signal. The intensity of this coloured product is directly proportional to the concentration of TP (p) present in the original sample. Rigorous validation Each batch manufactured from this ELISA kit is tested for quality for criteria such as sensitivity, specificity, accuracy and batch-to-batch consistency. See the product manual for more information on validation.
CD80 (B7-1) and CD86 (B7-2) are critical CD28 costimulation molecule ligands of T cells and CTLA-4 inhibitor receptor (CD152). Both B7 molecules are expressed on professional antigen-presenting cells and are essential for T cell activation. These two molecules can also replace one another in this process. CD80 is rapidly induced on the surface of B cells activated in vitro, with B cell lines transformed by the Epstein Barr virus (EBV), with Burkitt lymphoma cell lines, with newly isolated follicular B lymphoma cells, T cells, and monocytes. The B7-1 antigen of B-cell activation provides regulatory signals for T-cells as a result of binding to the CD28 and CTLA4 ligands of T-cells. Diseases associated with CD80 protein dysfunction include epidermoid carcinoma of the gallbladder and myocarditis.
Sensitivity
Sensitivity of the dosage: 0.10 ng.
Measurement range
Dose range: 0.31-20.0 ng/ml.
Duration of dosing
Total duration of dosing: 3 h 10 min.
Reproducibility
Coefficient of variation intra-dose 7.2%, inter-dose 9.2%.
Technical specifications
| General |
| Brand | Invitrogen |
| Supplier ref. (Fisher Scientific) | 15531897 |
| Specifications |
| Accession number | P33681 |
| Dose range | 0.31-20.0 ng/ml |
| Sensitivity of the dosage | 0.10 ng |
| Conjugate | HRP |
| Product type | Kit ELISA |
| Type of sample | Serum, Surnatant, Supernatant |
| Target species | Human |
| For use with (application) | ELISA |
| For use with (equipment) | Colorimetric microplate reader |
| Genetic identification (Enter) | 941 |
| Gene symbol(s) | B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7 |
| Coefficient of inter-dose variation | 9.2% |
| Coefficient of intra-dose variation | 7.2% |
| Contents of kits | Antibodies detection, Adhesive plate covers, Sample thinner, Sample thinner, Stop solution, 96 well pre-coated microplate, 96 well pre-coated microplate, Wash buffer concentrate, Substrate solution, Substrate solution, Buffer Lysis 10x |
| Marker or dye | HRP |
| Quantity | 128 Tests |
| Regulatory status | RUO |
| Synonym | CD28 Ligand1, lymphocyte antigen B7-1 |
| Target | Human |
| Test time | 20 min |
| Physical characteristics |
| Volume of sample | Plasma, 50 μl; Serum, 50 μl; Supernatant, 50 μl |
| Storage and shipping |
| Storage conditions | -20°C |
| Total duration of dosing | 3 h 10 min |
Origin and customs
| Manufacturer ref. | BMS291INST |
|---|
| Country of origin | Autriche |
|---|
| HS customs code | 3002 15 00 00 |
|---|
A question or a specific configuration?
Contact us for a quote.